...
首页> 外文期刊>Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus >Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus.
【24h】

Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus.

机译:食管癌多式联运治疗中两种分级方案的比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Multimodal therapy is increasingly utilized in the management of esophageal cancer. The optimum dose and fraction is unclear, and this retrospective analysis compared two radiation regimens in multimodality regimens where the chemotherapy arm and the type and magnitude of surgery was constant. Ninety-three consecutive patients with squamous cell carcinoma or adenocarcinoma of the esophagus were reviewed. Forty patients received the conventional unit regimen of 44 Gy in 22 daily fractions (2 Gy/fraction), and 40 patients received an increased dose per fraction (40 Gy in 15 daily fractions [2.67 Gy/fraction]). All patients received two courses of 5-fluorouracil and cisplatin and surgery was carried out within 8 weeks of completing therapy. The median overall survival in the group receiving the increased dose per fraction group was 25 months compared with 17 months in the conventional dose per fraction group (P=0.08). At 1, 3, and 5 years, 66%, 38%, and 38%, of patients in the increased dose per fraction group were alive, compared with 65%, 18%, and 15% in the conventional dose per fraction group (P=0.13), respectively. In the conventional dose per fraction group, two patients developed esophageal fistulae and one patient died postoperatively due to hemorrhage from an aorto-enteric fistula. There were no significant differences observed between treatment groups, but a trend toward improved efficacy appeared with the increased dose per fraction.
机译:多模式疗法越来越多地用于食道癌的治疗。最佳剂量和分数尚不清楚,该回顾性分析比较了多模式方案中的两种放疗方案,其中化疗组以及手术的类型和大小是恒定的。连续检查了93例食管鳞状细胞癌或腺癌患者。四十例患者接受了传统的单位治疗方案,即每天22次(44 Gy)(2 Gy /次),而40名患者接受了更高的剂量/剂量(40次Gy(15日)[2.67 Gy /次])。所有患者接受5-氟尿嘧啶和顺铂两个疗程,并且在完成治疗后的8周内进行了手术。接受每级剂量增加的组中位总生存期为25个月,而常规每级剂量组为17个月(P = 0.08)。在第1、3和5年,每级剂量增加剂量组中有66%,38%和38%的患者还活着,而每级常规剂量剂量组中分别有65%,18%和15%的患者存活( P = 0.13)。在常规的每部分剂量组中,有2例患者出现了食管瘘,并且1例由于主动脉-肠瘘出血而在手术后死亡。在治疗组之间没有观察到显着差异,但是随着每部分剂量的增加,出现了改善疗效的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号